BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//MedNet - ECPv6.15.20//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:MedNet
X-ORIGINAL-URL:https://mednetus.net
X-WR-CALDESC:Events for MedNet
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/New_York
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20230312T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20231105T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20240310T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20241103T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20250309T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20251102T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20260308T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20261101T060000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240210
DTEND;VALUE=DATE:20250211
DTSTAMP:20260423T133927
CREATED:20250620T074507Z
LAST-MODIFIED:20250620T074507Z
UID:10000018-1707523200-1739231999@mednetus.net
SUMMARY:New Prospects in Blood-based Biomarkers and Disease-Modifying Anti-Amyloid Antibody Therapies for Early-Stage Alzheimer’s Disease
DESCRIPTION:February 10\, 2024 \n\n\nTake Me to the Event Registration\n\n\nEVENT Summary \nDates \nSaturday\, February 10\, 2024\, 11:00 AM ET\, 10:00 AM CT\, and 9:00 AM MT \nLocation \nVirtual \nTarget Audience \nNeurologists\, nurse practitioners\, and physician assistants involved in Alzheimer’s disease patient care. \nFormat \nZoom Webinar \nCredits \n1.50 / AMA PRA Category 1 Credit(s)TM \nCost \nFree \nProgram Description \nClick to Go to the Event Registration \nThis webinar provides an update on the blood-based markers (BBMs) improve randomized clinical trials (RCTs) design and conduct of Alzheimer’s disease. It remains to be determined if the data available on BBMs are strong enough to replace CSF and PET biomarkers as entry criteria and monitoring tools in RCTs. Strategies to optimize and guide disease-modifying anti-amyloid antibody (AAA) therapies based on BBMs in managing patients with early-stage AD. \nAgenda \n\nDiscuss the blood-based biomarkers in diagnosing early-stage Alzheimer’s disease (AD) and its utility in the prevention – Jeremy Pruzin\, MD\nDiscuss clinical trial data on safety-efficacy profiles of approved and investigational disease-modifying anti-amyloid antibody therapies in managing early AD – Marwan Sabbagh\, MD\n\nIntended Audience \nNeurologists\, nurse practitioners\, and physician assistants involved in Alzheimer’s disease patient care. \nCommercial Supporter \nSupported by an educational grant from Eisai\, Inc. \nLearning Objectives \n\nSummarize the pathophysiology and the clinical presentation of Alzheimer’s disease (AD).\nAssess the blood-based biomarkers in diagnosing early-stage AD and its utility in the prevention.\nIdentify strategies to optimize disease-modifying anti-amyloid antibody (AAA) therapies in managing patients with early-stage AD.\n\nAccredited Providers \nAmedco and MedNet have collaborated to design and execute this activity. \n       \nPhysicians (ACCME) Credit \n\nJoint Accreditation Statement \nIn support of improving patient care\, this activity has been planned and implemented by Amedco LLC and MedNet. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME)\, the Accreditation Council for Pharmacy Education (ACPE)\, and the American Nurses Credentialing Center (ANCC)\, to provide continuing education for the healthcare team. Amedco Joint Accreditation #4008163. \n\n\nDesignation Statement \nAmedco LLC designates this live activity for a maximum of 1.50 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.\nAdditional Credit Information \nPhysician Assistants\nPAs may claim a maximum of 1.5 Category 1 credits for completing this activity. NCCPA accepts AMA PRA Category 1 CreditTM from organizations accredited by ACCME or a recognized state medical society. \nNurse Practitioners\nThe American Association of Nurse Practitioners (AANP) recognizes the Accreditation Council for Continuing Medical Education (ACCME) and the American Nurses Credentialing Center (ANCC) as approved accreditors and allow reciprocity for AANPCP continuing education credit. 1.5 hours. \nDisclosures of Relationships with Ineligible Companies Policy \nIn accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education\, all faculty\, planning committee members\, and other individuals\, who are in a position to control content\, are required to disclose all relationships with ineligible companies* (commercial interests) within the last 24 months. All educational materials are reviewed for fair balance\, scientific objectivity\, and levels of evidence. The ACCME requires us to disqualify from involvement in the planning and implementation of accredited continuing education any individuals (1) who refuse to provide this information or (2) whose conflicts of interests cannot be mitigated. \nOff-Label Disclosure Statement \nFaculty members are required to inform the audience when they are discussing off-label\, unapproved uses of devices and drugs. Physicians should consult full prescribing information before using any product mentioned during this educational activity. \nFaculty \n \nJeremy Pruzin\, MD\nBehavioral Neurologist\nBanner Alzheimer’s Institute\nTucson\, AZ \n \nMarwan Sabbagh\, MD\nProfessor of Neurology\nBarrow Neurological Institute\nPhoenix\, AZ \nInstructions/Technical Requirements \n\nA desktop or laptop computer or a mobile device with a stable internet connection and audio capability is required to attend. Joining via mobile or tablet is possible but not recommended.\nTimes in the portal adjust to your computer; however\, some browsers have a separate time zone adjustment.\nFor the best viewing experience\, we recommend the following browsers: Chrome\, Firefox\, and Safari. For attendees viewing on Internet Explorer 11\, you may experience lags in streaming. To maximize your attendee hub experience\, we recommend you not sign in through your company assigned VPN.\nEnsure that your computer’s sound is enabled for your browser and allow permissions to the On24 Attendee Hub platform if necessary.\n\nCost \nComplimentary \nContact \nBrian Waggoner\nProgram Manager\nMedNet\nbrianw@mmhus.net
URL:https://mednetus.net/event/new-prospects-in-blood-based-biomarkers-and-disease-modifying-anti-amyloid-antibody-therapies-for-early-stage-alzheimers-disease-2/
CATEGORIES:Live Program
ATTACH;FMTTYPE=image/jpeg:https://mednetus.net/wp-content/uploads/2025/06/lguvvkalmx2k-Banner800x450.jpg
END:VEVENT
END:VCALENDAR